Prostaglandin Analogues (PGAs) have often been regarded as pro-inflammatory and contraindicated in situations where there is risk of inflammation, such as neovascular glaucoma (NVG).
Chauhan et al have published a study to evaluate the risk of uveitis among patients starting on topical glaucoma therapy.
The retrospective study utilized the Sight Outcomes Research Collaborative (SOURCE) Ophthalmology Data Repository data from 10 health systems contributing to the SOURCE data repository.
Adult glaucoma patients who were recently started on topical glaucoma therapy were included in the study. The anti-glaucoma medications included prostaglandin analogs [PGAs], beta-blockers [BBs], alpha agonists [AAs], and carbonic anhydrase inhibitors [CAIs].
Patients with pre-existing documentation of uveitis were excluded.
The main outcome measure was the incidence of uveitis within 3 months of initiating therapy with different topical glaucoma medications.
The study included 67517 patients who were newly prescribed a topical glaucoma medication.
A total of 567 patients (0.87%) developed uveitis within 3 months of initiating the therapy.
The incidence of uveitis was 1.95%, 1.68%, 1.63%, and 0.32% for users of BBs, CAIs, AAs, and PGAs, respectively.
After adjusting for sociodemographic factors, individuals using topical BBs, AAs, and CAIs had significantly higher odds of developing uveitis versus those using PGAs (P < 0.001 for all comparisons).
The study concluded that the use of PGAs was not associated with higher odds of developing uveitis compared with other classes of topical glaucoma medications.
REFERENCE:
Chauhan MZ, Elhusseiny AM, Marwah S, Sallam AB, Stein JD, Kishor KS; SOURCE Consortium. Incidence of Uveitis Following Initiation of Prostaglandin Analogs versus Other Glaucoma Medications: A Study from the Sight Outcomes Research Collaborative Repository. Ophthalmol Glaucoma.2025;8:126-132.
No comments:
Post a Comment